Arvinas Inc.

Contributing Author

Recent Articles by Arvinas Inc.

Oct-01	Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders ARVN GlobeNewswire
Sep-29	Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ARVN GlobeNewswire
Sep-28	Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate ARVN GlobeNewswire
Sep-03	Arvinas to Participate in Upcoming Investor Conferences ARVN GlobeNewswire
Sep-01	Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ARVN GlobeNewswire
Aug-04	Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update ARVN +11.66% GlobeNewswire
Jul-28	Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 ARVN GlobeNewswire
Jun-04	Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease ARVN GlobeNewswire
May-29	Arvinas to Present at Jefferies Global Healthcare Conference ARVN GlobeNewswire
May-18	Arvinas Employees Give Back During Company-wide Impact Day ARVN GlobeNewswire
May-12	Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update ARVN GlobeNewswire
May-12	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) ARVN GlobeNewswire
May-05	Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 ARVN GlobeNewswire
May-01	Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer ARVN +6.16% GlobeNewswire
Mar-18	Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days ARVN -9.33% GlobeNewswire
Mar-11	Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ARVN GlobeNewswire
Feb-24	Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ARVN GlobeNewswire
Feb-23	Arvinas to Participate in Upcoming Investor Conferences ARVN GlobeNewswire
Feb-17	Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 ARVN GlobeNewswire
Feb-12	Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director ARVN -9.59% GlobeNewswire
Dec-06	Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition ARVN GlobeNewswire
Nov-26	Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference ARVN GlobeNewswire
Nov-24	Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) ARVN GlobeNewswire
Nov-05	Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update ARVN GlobeNewswire
Nov-03	Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting ARVN GlobeNewswire
Nov-03	Arvinas to Participate in Upcoming Investor Conferences ARVN GlobeNewswire
Oct-29	Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 ARVN GlobeNewswire
Oct-24	Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ARVN GlobeNewswire
Oct-22	Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ARVN GlobeNewswire
Oct-20	Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy ARVN GlobeNewswire
Oct-13	Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress ARVN GlobeNewswire
Oct-05	Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders ARVN GlobeNewswire
Oct-01	Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders ARVN +7.16% GlobeNewswire
Sep-17	Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation ARVN GlobeNewswire
Aug-29	Arvinas to Participate in Upcoming Investor Conferences ARVN GlobeNewswire
Aug-08	Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer ARVN GlobeNewswire
Aug-06	Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update ARVN -15.51% GlobeNewswire
Jul-30	Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 ARVN GlobeNewswire
Jul-09	Arvinas Announces Retirement of Chief Executive Officer and Succession Plan ARVN GlobeNewswire
Jun-13	Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress ARVN GlobeNewswire
Jun-06	Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer ARVN +8.82% GlobeNewswire
Jun-05	Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting ARVN GlobeNewswire
May-31	Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer ARVN GlobeNewswire
May-30	Arvinas to Present at Jefferies Global Healthcare Conference ARVN GlobeNewswire

Arvinas Inc.

Recent Articles by Arvinas Inc.

Upgrade your Finviz experience